Castilla y León allocates more than five million for herpes zoster vaccines – News files – iHealth

..Drafting.
The Governing Council of the Junta de Castilla y León has authorized the Ministry of Health to purchase 40,000 doses of herpes zoster vaccines with which to offer systematic vaccination to the population cohort that turns 65 during the current financial year. Thus, the criteria established for the whole of the National Health System are met. The Ministry of Health explains that “by 2022 it had been planned to extend the range of vaccination against herpes zoster to the general population that makes up the cohort of people who turn 65 throughout the current year.” To meet this forecast, the Junta de Castilla y León has contracted the acquisition of 40,000 units of this type of vaccine, for which the Governing Council has today authorized the file processed by the Ministry of Health valued at 5,052,424 euros. In this way, the General Directorate of Public Health will attend to the vaccine needs foreseen for this year. The vaccine schedule against herpes zoster consists of two doses. The acquisition of 40,000 doses of herpes zoster vaccines will make it possible to offer systematic vaccination to the population cohort that turns 65 years old Herpes zoster is a viral infection that has its origin in the varicella zoster virus and can affect any part of the body human. It presents with rashes, vesicles and pain, and can cause complications and disabling sequelae in those affected, including postherpetic neuralgia. This condition is characterized by chronic intense pain that can lead to other related symptoms. Shingles has a higher incidence after the age of 50, among women and in people with a depressed or weakened immune system. “It is not a life-threatening disease but it is highly painful and disabling, vaccination being a measure that reduces the risk of suffering from this disease,” they recall from the Ministry of Health. In this sense, vaccination against herpes zoster has been part of the vaccination calendar since mid-2021, having then been established as the group recommended for use, pending greater availability of doses worldwide, the group made up of people older than 18 years with risk conditions (patients with hematopoietic stem cell transplants, solid organ transplant recipients, users of anti-JAK drug treatments, people with HIV, malignant blood diseases and solid tumors undergoing chemotherapy). Complementary news